Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival
Especially patients with increasing selenium levels during radiotherapy showed an improved overall survival. Thus, serum selenium might be a predictive factor for OS in NSCLC patients. The value of supplementation of the trace element is subject to future research.
Authors
- Daniel Medenwald (ORCID: https://orcid.org/0000-0001-8920-2853)
- C. Ostheimer
- Lutz Schomburg (ORCID: https://orcid.org/0000-0001-9445-1555)
- Barbara Seliger (ORCID: https://orcid.org/0000-0002-5544-4958)
- Dirk Vordermark (ORCID: https://orcid.org/0000-0001-8816-0508)
- Kamil Demircan (ORCID: https://orcid.org/0000-0003-2256-7019)
- Matthias Bache (ORCID: https://orcid.org/0000-0002-5912-9584)
- Therese Tzschoppe
- Julia Ohlinger
Institutions
- Fraunhofer Institute for Cell Therapy and Immunology (DE)
- Medizinische Hochschule Brandenburg Theodor Fontane (DE)
- University Hospital in Halle (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Strahlentherapie und Onkologie
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1007/s00066-024-02276-w
- Citations
- 2
- Primary Topic
- Selenium in Biological Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.62